Search for: "Tom Lamb"
Results 1 - 20
of 1,051
Sort by Relevance
|
Sort by Date
30 Sep 2024, 11:02 am
Federal Appeals Court Rejects Merck's Legal Defense of Federal Preemption in September 2024 (Posted by Tom Lamb at Drug Injury Watch) A federal appeals court ruled in September 2024 that more than 500 plaintiffs should have their Fosamax femur fracture drug injury lawsuits reinstated and sent back to the current judge presiding over the federal court Fosamax MDL litigation. [read post]
12 Sep 2024, 1:40 pm
August 2024 Veozah Drug Label Change Adds Warnings About Liver Toxicity and Abnormal Liver Tests (Posted by Tom Lamb at Drug Injury Watch) On September 12, 2024, the FDA announced a warning about the rare occurrence of serious liver injury when a woman is using Veozah for hot flashes due to menopause. [read post]
26 Aug 2024, 9:15 am
Drug Company Apellis Failed to Warn About Retinal Vasculitis Until a November 2023 Label Change (Posted by Tom Lamb at Drug Injury Watch) We are handling Syfovre injections side effects legal compensation cases being filed for patients The basis for these product liability personal injury lawsuits is the drug company Apellis failed to warn about retinal vasculitis until a November 2023 label change. [read post]
18 Jul 2024, 12:53 pm
Growing Number of Pulmonary Embolism and DVT Cases Involving Semaglutide Reported by Patients (Posted by Tom Lamb at Drug Injury Watch) Wegovy, Rybelsus, and Ozempic have been associated with an increased risk of blood clots that can lead to pulmonary embolism (sometimes called PE) and deep vein thrombosis (often called DVT). [read post]
5 Jul 2024, 9:30 am
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), or "Eye Stroke", Can Cause Vision Loss (Posted by Tom Lamb at Drug Injury Watch) Wegovy, Rybelsus, and Ozempic eye side effects are possible given the recent finding that the active ingredient of these three drugs semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION). [read post]
28 Jun 2024, 11:45 am
EMA’s CHMP Does Not Approve Syfovre for a Second Time, Citing "significant risk of adverse events" (Posted by Tom Lamb at Drug Injury Watch) There seems to be some disagreement about the Syfovre safety-benefit assessment when it comes to the US FDA and its European counterpart, the European Medicines Agency (EMA). [read post]
14 May 2024, 2:07 pm
Semaglutide-related Side Effects Include Ischemic Stroke, Pulmonary Embolism, and Deep Vein Thrombosis (Posted by Tom Lamb at Drug Injury Watch) Wegovy, Rybelsus, and Ozempic are drugs with semaglutide as their active ingredient. [read post]
24 Apr 2024, 11:30 am
She Went to the Local ER With Loss of Vision 11 Days After Receiving an Intravitreal Syfovre (Pegcetacoplan) Injection (Posted by Tom Lamb at Drug Injury Watch) In the March 2024 edition of the American Journal of Ophthalmology Case Reports medical journal, there is a Syfovre retinal vaso-occlusive vasculitis case report involving a 78-year old woman with vision loss that happened back in the first part of 2023. [read post]
24 Apr 2024, 5:57 am
This autocracy threat tracker is also available as a PDF file. [read post]
4 Apr 2024, 11:52 am
Retinal Vasculitis After Syfovre Injections: Etiology is Still Unknown and Incidence Rate Remains Unclear (Posted by Tom Lamb at Drug Injury Watch) Syfovre (pegcetacoplan) was approved by the FDA in February 2023 as an eye injection to treat geographic atrophy (GA), a relatively rare condition secondary to age-related macular degeneration. [read post]
8 Mar 2024, 3:00 am
National/Federal Nikki Haley Suspends Her Campaign and Leaves Donald Trump as the Last Major Republican Candidate Associated Press News – Steve Peoples and Meg Kinnard | Published: 3/6/2024 Nikki Haley suspended her presidential campaign after being soundly defeated across the country on Super Tuesday, leaving Donald Trump as the last remaining major candidate for the 2024 Republican nomination. [read post]
6 Mar 2024, 12:10 pm
Pre-Existing Allergy Toward Polyethylene Glycol (PEG) is Most Recent Causation Theory Offered by Apellis (Posted by Tom Lamb at Drug Injury Watch) In late January 2024, a leading medical journal for ophthalmologists and retina specialists, the Journal of VitreoRetinal Diseases, published this Syfovre case report, "Occlusive Retinal Vasculitis After a Single Injection of Pegcetacoplan", written by three authors affiliated with the Department of… [read post]
22 Feb 2024, 10:10 am
Research Finding: Semaglutide Increased the Risk of Deep Vein Thrombosis (DVT) by 266% in Patients with Type 2 Diabetes (Posted by Tom Lamb at Drug Injury Watch) Semaglutide-containing drugs that are being used for weight loss purposes include Ozempic, Rybelsus, and Wegovy. [read post]
9 Feb 2024, 12:03 pm
Learn About Related Symptoms and Diagnosis Process for Gastroparesis, a Side Effect of Ozempic, Wegovy, Rybelsus, and Trulicity (Posted by Tom Lamb at Drug Injury Watch) In this article, we present some gastroparesis case reports involving the use of GLP-1 receptor agonists semaglutide (e.g., Ozempic, Wegovy, Rybelsus) or dulaglutide (e.g., Trulicity) that have been published recently by medical journals. [read post]
19 Jan 2024, 12:48 pm
Prolia "Black Box" Warning: Harm From Severe Hypocalcemia Ranges From Hospitalization For Life-threatening Events To Death (Posted by Tom Lamb at Drug Injury Watch) A January 2024 JAMA Original Investigation article, "Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients", in summary, presents evidence of a Prolia increased risk of hypocalcemia in patients with chronic kidney disease (CKD) that can be… [read post]
Syfovre Safety Issues Need More Attention Before This Relatively New Eye Drug Gets Widely Prescribed
27 Dec 2023, 1:15 pm
December 2023 JAMA Ophthalmology Viewpoint Piece About Syfovre Calls for Independent and Unbiased Evaluation (Posted by Tom Lamb at Drug Injury Watch) Since the February 2023 FDA approval of Syfovre (pegcetacoplan), Apellis Pharmaceuticals has had to contend with various Syfovre safety issues related to its eye injection treatment for geographic atrophy. [read post]
4 Dec 2023, 2:01 pm
November 2023 Syfovre Label Change Comes After Earlier Reports of Eye Inflammation and Severe Vision Loss (Posted by Tom Lamb at Drug Injury Watch) We have been writing about Syfovre drug safety developments having to do with retinal vasculitis cases and other eye-related side effects since July 2023. [read post]
10 Nov 2023, 2:55 pm
A Syfovre Case of Hemorrhagic Occlusive Vasculitis-type Inflammation With Continued Blindness Is Reported (Posted by Tom Lamb at Drug Injury Watch) At the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO), various Syfovre patients eye side effects cases were discussed by William J. [read post]
30 Oct 2023, 8:51 am
Here is my annual list of Halloween torts and crimes. [read post]
24 Oct 2023, 3:20 pm
Researchers Compared Semaglutide Drugs, Such as Ozempic and Wegovy, to Contrave, a Non-GLP-1 Drug, in Weight-Loss Patients (Posted by Tom Lamb at Drug Injury Watch) An October 2023 medical journal article presented the results of a recent study comparing patients who used two different types of weight-loss drugs to see whether drugs containing the GLP-1 semaglutide showed Ozempic and Wegovy associated with gastroparesis, a gastrointestinal condition… [read post]
